Actively Recruiting
A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors
Led by Shenyang Sunshine Pharmaceutical Co., LTD. · Updated on 2025-04-29
154
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.
CONDITIONS
Official Title
A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically and/or cytologically documented locally advanced, recurrent, or metastatic malignancies
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Expected survival of more than 3 months
- Signed informed consent form
- Adequate organ function
You will not qualify if you...
- Any remaining adverse events greater than grade 1 from prior anti-tumor treatment, except hair loss and fatigue
- Pregnant or nursing women, or men and women who are ready to have children
- Symptomatic central nervous system metastasis
- Allergy to other antibody drugs or any excipients in the study drug
- Major surgery within 4 weeks before first dose
- Participation in another clinical study unless observational or follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
Q
Qi Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here